Debt to Equity Ratio Chart

View Debt to Equity Ratio for CRBP.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Debt to Equity Ratio Chart
Start Trial

Historical Debt to Equity Ratio Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 0.0417
March 31, 2026 0.0095
December 31, 2025 0.0111
September 30, 2025 0.0222
June 30, 2025 0.0221
March 31, 2025 0.0225
December 31, 2024 0.0227
September 30, 2024 0.024
June 30, 2024 0.1179
March 31, 2024 0.1783
December 31, 2023 -3.025
September 30, 2023 73.49
June 30, 2023 2.491
March 31, 2023 1.509
December 31, 2022 0.7605
September 30, 2022 0.6084
June 30, 2022 0.5203
March 31, 2022 0.4279
December 31, 2021 0.3848
September 30, 2021 0.3337
June 30, 2021 0.3389
March 31, 2021 0.2892
December 31, 2020 0.5927
September 30, 2020 0.8959
June 30, 2020 0.1775
Date Value
March 31, 2020 0.3982
December 31, 2019 1.534
September 30, 2019 0.2809
June 30, 2019 0.1629
March 31, 2019 0.1789
December 31, 2018 0.0143
September 30, 2018 0.00
June 30, 2018 0.0016
March 31, 2018 0.0032
December 31, 2017 0.0058
September 30, 2017 0.0002
June 30, 2017 0.0012
March 31, 2017 0.0037
December 31, 2016 0.0314
September 30, 2016 0.0007
June 30, 2016 0.0019
March 31, 2016 0.0164
December 31, 2015 0.018
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.0155
December 31, 2014 0.0246
September 30, 2014 0.0107
June 30, 2014 0.0857
March 31, 2014

Debt to Equity Ratio Definition

The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.

Read full definition.

Debt to Equity Ratio Range, Past 5 Years

View Debt to Equity Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Debt to Equity Ratio Benchmarks

View Debt to Equity Ratio Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 0.0565
Alnylam Pharmaceuticals, Inc. 2.206
Anika Therapeutics, Inc. 0.1839
Savara, Inc. 0.2117
Vericel Corp. 0.2556